|
시장보고서
상품코드
2039086
특발성 과다수면증 치료 시장 : 약물 종류별, 유통 채널별, 지역별Idiopathic Hypersomnia Treatment Market, By Drug Class, By Distribution Channel, By Geography |
||||||
특발성 과다수면증 치료 시장은 2026년에 3억 9,470만 달러로 추정되며, 2033년까지 7억 960만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 3억 9,470만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 8.70% | 2033년 시장 규모 예측: | 7억 960만 달러 |
특발성 과다수면증은 충분한 수면이나 장시간 수면을 취한 후에도 낮에 과도한 졸음을 느끼는 희귀한 수면 질환입니다. 또한 야간 수면이나 낮잠을 자고 난 후 환자가 깨어나는 데 어려움을 겪을 수 있습니다. 또한, 기면증과 특발성 과다수면증은 모두 과수면증의 일종이지만 수면다원검사(PSG)와 같은 진단 검사로 확인할 수 있는 수면다원검사(PSG)를 통해 수면시작시 렘수면기간(SOREMP)의 수에서 차이가 있습니다. 기면증 환자는 수면다원검사(PSG) 및 다중수면잠복기검사(MSLT) 결과에서 2회 이상의 SOREMP가 관찰되지만, 특발성 과다수면증 환자에서는 관찰되지 않습니다. 특발성 과다수면증에 대해서는 각성도를 높이는 등의 대증요법이 있지만, 이 질환에 대해 승인된 약물은 하나도 없습니다.
시장 역학
파이프라인 제품 수의 증가와 생활습관병 사례의 증가는 세계 특발성 과다수면증 치료제 시장을 이끄는 주요 요인 중 일부입니다. 예를 들어, 2020년 10월 재즈 파마슈티컬스는 특발성 과다수면증 치료제 Xywav(칼슘, 마그네슘, 칼륨 및 나트륨 옥시버트를 함유한 특발성 과다수면증 치료제인 Xywav(칼슘, 마그네슘, 칼륨 및 나트륨 옥시버트를 함유한 특발성 과다수면증 치료제)의 3상 임상에서 주요 평가변수(Epworth Sleepiness Scale(ESS)) 및 주요 부수적 평가변수[환자 전반적 개선도(PGIc) 및 특발성 과다수면증 중증도 척도(IHSS)]를 달성한 양호한 탑라인 결과를 발표했습니다.
본 시험의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 특발성 과다수면증 치료제 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 발전, 전략 및 미래 계획입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 특발성 과다수면증 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 특발성 과다수면증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 특발성 과다수면증 치료 시장 : 약물 종류별, 2021-2033년
제5장 세계의 특발성 과다수면증 치료 시장 : 유통 채널별, 2021-2033년
제6장 세계의 특발성 과다수면증 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.04Idiopathic Hypersomnia Treatment Market is estimated to be valued at USD 394.7 Mn in 2026 and is expected to reach USD 709.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 394.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.70% | 2033 Value Projection: | USD 709.6 Mn |
Idiopathic hypersomnia is a rare sleep disease that causes a person to be excessively sleepy during the day even after a good or prolonged night's sleep. It also causes difficulty in waking up among patients after a night sleep or a nap. Moreover, narcolepsy and idiopathic hypersomnia are both types of hypersomnia but there are differences, which can be observed by diagnostic tests such as Polysomnography (PSG) that lies in the number of sleep-onset REM periods (SOREMPs). Patients with narcolepsy have two or more SOREMPs from Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, whereas patients with idiopathic hypersomnia do not. There are symptomatic treatment such as increase wakefullness options available for idiopathic hypersomnia, while there is not a single approved drugs for this disease.
Market Dynamics
Rising number of pipeline products and increasing cases of lifestyle diseases are some of the major factors responsible for growth of the global idiopathic hypersomnia treatment Market. For instance, in October 2020, Jazz Pharmaceuticals announced positive topline results from a phase 3 study evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia that showed that the trial met the primary point (measured Epworth Sleepiness Scale (ESS)) and key secondary end points [Patient Global Impression of Change (PGIc) and Idiopathic Hypersomnia Severity Scale (IHSS)].
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global idiopathic hypersomnia treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global idiopathic hypersomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global idiopathic hypersomnia treatment Market
Idiopathic Hypersomnia Treatment Market Segmentation
- By Drug Class
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Idiopathic Hypersomnia Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- BIOPROJET
- Avadel Pharmaceuticals plc
- GlaxoSmithKline plc
- Pfizer Inc.
- Theranexus
- Fisher & Paykel Healthcare Limited
- Drive DeVilbiss Healthcare LLC
- Merck & Co., Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- CKD Stages Treatment Options
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Market Trends
- Recent Product Launch/Approvals
- Cost of Treatment
- Regulatory Scenario
- PEST Analysis
- Mergers, Acquisitions, and Partnerships
- Epidemiology
- Reimbursement Scenario (Medicare Part D Spending)
4. Global Idiopathic Hypersomnia Treatment Market, By Drug Class, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Stimulant Medications
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Non-stimulant wake-promoting Medications
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Sodium Oxybate
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Idiopathic Hypersomnia Treatment Market, By Region, 2021-2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- U.S.
- Canada
- Latin America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- South Africa
- Central Africa
- North Africa
7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Jazz Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BIOPROJET
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Avadel Pharmaceuticals, Plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc,
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Theranexus
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fisher & Paykel Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Innovation Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Drive DeVilbiss Healthcare LLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
8. Section
- Research Methodology
- About us and Sales Contact
